51. Scleroderma Clinical trials / Disease details
Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05298358 (ClinicalTrials.gov) | November 18, 2022 | 7/3/2022 | RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis | A Phase I Study of Reduced Intensity Conditioning Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis | Systemic Sclerosis | Biological: RIC alloBMT w PTCy in refractory SSc | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NULL | Recruiting | 18 Years | 65 Years | All | 30 | Phase 1 | United States |